AU2015222846B2 - Peptides and methods of use - Google Patents
Peptides and methods of use Download PDFInfo
- Publication number
- AU2015222846B2 AU2015222846B2 AU2015222846A AU2015222846A AU2015222846B2 AU 2015222846 B2 AU2015222846 B2 AU 2015222846B2 AU 2015222846 A AU2015222846 A AU 2015222846A AU 2015222846 A AU2015222846 A AU 2015222846A AU 2015222846 B2 AU2015222846 B2 AU 2015222846B2
- Authority
- AU
- Australia
- Prior art keywords
- peptide
- protein
- amino acid
- peptides
- tie
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461946103P | 2014-02-28 | 2014-02-28 | |
| US61/946,103 | 2014-02-28 | ||
| PCT/US2015/018041 WO2015131061A1 (en) | 2014-02-28 | 2015-02-27 | Peptides and methods of use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2015222846A1 AU2015222846A1 (en) | 2016-08-25 |
| AU2015222846B2 true AU2015222846B2 (en) | 2019-09-19 |
Family
ID=52633723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2015222846A Active AU2015222846B2 (en) | 2014-02-28 | 2015-02-27 | Peptides and methods of use |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US9447147B2 (OSRAM) |
| EP (1) | EP3110841B1 (OSRAM) |
| JP (1) | JP6711761B2 (OSRAM) |
| KR (1) | KR20160126075A (OSRAM) |
| CN (1) | CN106232615B (OSRAM) |
| AU (1) | AU2015222846B2 (OSRAM) |
| BR (1) | BR112016019484A2 (OSRAM) |
| CA (1) | CA2939658C (OSRAM) |
| EA (1) | EA201691749A1 (OSRAM) |
| ES (1) | ES2873956T3 (OSRAM) |
| IL (1) | IL247448B (OSRAM) |
| MX (1) | MX385558B (OSRAM) |
| PH (1) | PH12016501608B1 (OSRAM) |
| SG (2) | SG10201807066UA (OSRAM) |
| WO (1) | WO2015131061A1 (OSRAM) |
| ZA (1) | ZA201605518B (OSRAM) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12441810B2 (en) | 2020-05-05 | 2025-10-14 | Vega Therapeutics, Inc. | Protein S antibodies, methods of making and uses thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014190860A1 (zh) * | 2013-05-29 | 2014-12-04 | 四川大学 | 人源egf结构域蛋白及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5321123A (en) * | 1991-07-02 | 1994-06-14 | The Scripps Research Institute | Protein S polypeptides and anti-peptide antibodies that inhibit protein S binding to C4B binding protein, diagnostic systems and therapeutic methods |
| SE9604378D0 (sv) * | 1996-11-27 | 1996-11-27 | Tac Ab | Methods and reagents for determining protein S |
| WO2003039587A1 (en) * | 2001-11-09 | 2003-05-15 | Novo Nordisk Health Care Ag | Pharmaceutical composition comprising factor vii polypeptides and protein s inhibitors |
| EP2547355B1 (en) * | 2010-03-19 | 2017-01-11 | Baxalta GmbH | Tfpi inhibitors and methods of use |
| US9073990B2 (en) * | 2010-04-05 | 2015-07-07 | Bar-Llan University | Protease-activatable pore-forming polypeptides |
| EP2827883B1 (en) | 2012-03-21 | 2019-05-08 | Baxalta GmbH | Tfpi inhibitors and methods of use |
-
2015
- 2015-02-27 CN CN201580011074.8A patent/CN106232615B/zh not_active Expired - Fee Related
- 2015-02-27 BR BR112016019484A patent/BR112016019484A2/pt not_active Application Discontinuation
- 2015-02-27 PH PH1/2016/501608A patent/PH12016501608B1/en unknown
- 2015-02-27 ES ES15709067T patent/ES2873956T3/es active Active
- 2015-02-27 US US14/634,028 patent/US9447147B2/en active Active
- 2015-02-27 EP EP15709067.1A patent/EP3110841B1/en active Active
- 2015-02-27 SG SG10201807066UA patent/SG10201807066UA/en unknown
- 2015-02-27 AU AU2015222846A patent/AU2015222846B2/en active Active
- 2015-02-27 IL IL247448A patent/IL247448B/en unknown
- 2015-02-27 JP JP2016552533A patent/JP6711761B2/ja active Active
- 2015-02-27 EA EA201691749A patent/EA201691749A1/ru unknown
- 2015-02-27 MX MX2016011174A patent/MX385558B/es unknown
- 2015-02-27 CA CA2939658A patent/CA2939658C/en active Active
- 2015-02-27 WO PCT/US2015/018041 patent/WO2015131061A1/en not_active Ceased
- 2015-02-27 KR KR1020167026913A patent/KR20160126075A/ko not_active Ceased
- 2015-02-27 SG SG11201607067TA patent/SG11201607067TA/en unknown
-
2016
- 2016-08-10 ZA ZA2016/05518A patent/ZA201605518B/en unknown
- 2016-08-19 US US15/242,002 patent/US10124033B2/en active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014190860A1 (zh) * | 2013-05-29 | 2014-12-04 | 四川大学 | 人源egf结构域蛋白及其应用 |
Non-Patent Citations (2)
| Title |
|---|
| Hackeng T.M. et al. "Chemical synthesis of human protein S thrombin-sensitive module and first epidermal growth factor module" Biopolymers (1998) 46: 53-63 * |
| Takahashi M. et al. "Epitope mapping and characterization of monoclonal antibodies to human protein C" Biochimica et Biophysica Acta (1993) 1161: 113-123 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN106232615A (zh) | 2016-12-14 |
| JP2017509602A (ja) | 2017-04-06 |
| ES2873956T3 (es) | 2021-11-04 |
| SG11201607067TA (en) | 2016-10-28 |
| SG10201807066UA (en) | 2018-09-27 |
| CA2939658C (en) | 2022-10-04 |
| KR20160126075A (ko) | 2016-11-01 |
| BR112016019484A2 (pt) | 2017-10-24 |
| EA201691749A1 (ru) | 2016-12-30 |
| US20150246947A1 (en) | 2015-09-03 |
| IL247448B (en) | 2022-09-01 |
| WO2015131061A1 (en) | 2015-09-03 |
| CN106232615B (zh) | 2021-06-01 |
| MX2016011174A (es) | 2016-11-15 |
| AU2015222846A1 (en) | 2016-08-25 |
| US9447147B2 (en) | 2016-09-20 |
| US20170035835A1 (en) | 2017-02-09 |
| EP3110841A1 (en) | 2017-01-04 |
| ZA201605518B (en) | 2018-12-19 |
| CA2939658A1 (en) | 2015-09-03 |
| EP3110841B1 (en) | 2021-03-31 |
| US10124033B2 (en) | 2018-11-13 |
| PH12016501608A1 (en) | 2016-10-03 |
| JP6711761B2 (ja) | 2020-06-17 |
| PH12016501608B1 (en) | 2022-07-01 |
| IL247448A0 (en) | 2016-11-30 |
| MX385558B (es) | 2025-03-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK2547355T3 (en) | TFPI INHIBITORS AND METHODS OF USE | |
| JP6567577B2 (ja) | Ｔｆｐｉインヒビターおよび使用法 | |
| US10800816B2 (en) | TFPI inhibitors and methods of use | |
| US10124033B2 (en) | Peptides and methods of use | |
| EA041584B1 (ru) | Пептиды, ингибирующие активность белка s, и их применение для лечения нарушения свертывания крови | |
| HK1206282B (en) | Tfpi inhibitors and methods of use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| PC | Assignment registered |
Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED Free format text: FORMER OWNER(S): BAXALTA GMBH; BAXALTA INCORPORATED |